JPH0899863A - Use of fatty acid for duplicate infection of skin - Google Patents

Abstract

PROBLEM TO BE SOLVED: To obtain a cosmetic or dermatologic preparation containing a specific mixture as an active ingredient, not producing a side effect, and useful for controlling opportunistic or pathogenic pathogens to treat skin superinfections, etc. SOLUTION: This cosmetic or dermatologic preparation contains as an active ingredient a mixture of (A) dodecanoic acid (lauric acid) with (B) one or more fatty acids selected from the group consisting of nonbranched saturated fatty acids having 6-20C chain lengths, in a pH range of η8, excluding (C) glycerol fatty acid esters, ethoxylated glycerol fatty acid esters and propoxylated glycerol fatty acid esters.

Description

Detailed Description of the Invention

[0001]

The present invention relates to active compounds against superinfection of the skin, as well as dermatological preparations containing such active compounds.

[0002]

BACKGROUND OF THE INVENTION Healthy human skin is inhabited by a large number of non-pathogenic microorganisms. This so-called skin microflora is not only harmless, but represents an important defense mechanism for the protection against opportunistic or pathogenic pathogens.

For example, Staphyloco
cci ) is often a physiological pathogen, but is also often a non-physiological pathogen, such as Candida albicans. A “superinfection” of infected skin can occur when a new infection with a pathogen count occurs with an existing primary infection, ie, the normal pathogen population of the skin, as well as with a concomitant adverse infection. The normal microflora of the skin (or other organs of the body) is then substantially overgrown by secondary pathogens.

In cases where it progresses expediently, such superinfections may exhibit unpleasant cutaneous symptoms (itching, external appearance) depending on the pathogen concerned. However, in the case of unfavorable progress, these can lead to extensive skin destruction and, in the worst case, even the death of the patient.

Superinfections of the type described above are secondary diseases that often occur, for example, with the full complement of AIDS. Pathogens that are harmless by themselves at any percentage of low pathogen density, but are also clearly pathogenic under certain circumstances, overgrow healthy skin microflora in this manner. Let Of course, in the case of AIDS, other organs of the body are also affected by superinfection.

[0006] Such superinfections are also observed with a large number of dermatological diseases such as atopic eczema, neurodermatitis, acne, seborrheic dermatitis, or psoriasis. Many medical and therapeutic treatments, including radiotherapy or chemotherapy for cancer diseases, drug-induced and side effects immunosuppression, or systemic antibiotic therapy, as well as external chemical or physical effects (Eg environmental pollution, smog) also enhances the development of superinfections of external and internal organs, especially the skin and mucous membranes.

In the individual case, it is also possible to eliminate the superinfection with antibiotics, but such substances usually have the disadvantage of unpleasant side effects. For example, patients are often allergic to penicillin, and for this reason related treatments would be contraindicated in such cases.

Topically-administered antibiotics further remove these secondary pathogens from the skin microbiota as well as the skin microbiota that are themselves physiological, and naturally It also has the disadvantage that the healing process is slowed down again in this manner.

[0009]

The object of the present invention is to eliminate the drawbacks of the prior art and to use them to cure superinfections without incurring any apparent loss of physiological skin microflora. And to provide formulations containing such substances.

The object of the present invention was also to provide substances which act prophylactically against superinfection, as well as cosmetic and dermatological preparations which contain such substances.

[0011]

[Means for Solving the Problems] Surprisingly, (a)
(C) Fatty acid ester of glycerol, ethoxyl, with dodecanoic acid (lauric acid) and (b) at least one other fatty acid selected from the group consisting of unbranched saturated fatty acids having a chain length of C _6-20 The use of the active ingredients of the mixture of (d) within the pH range of 8 or less, in which the fatty acid ester of glycated glycerol and the fatty acid ester of propoxylated glycerol are excluded as active ingredients against superinfection of skin, It has been found to improve the drawbacks, and thus all these objectives are achieved.

[0012] German Patent Application No. 42 29 737 does indeed mention (a) dodecanoic acid (lauric acid) and (b) C.
(C) a fatty acid ester of glycerol, a fatty acid ester of ethoxylated glycerol, and a propoxylated glycerol of at least one other fatty acid selected from the group consisting of unbranched saturated fatty acids having a chain length of _6-20. The use of an active ingredient of a mixture of (d) within a pH range of 8 or less, excluding fatty acid esters, as an active ingredient in a cosmetic deodorant is described, but the specification described is a skin overlap. No mention is made of its activity in the context of an agent for combating sensations. Rather,
The teachings of the specification described are mainly coryneform.
neform) selective activity of such a mixture against bacteria.

EP-A-0 243 145 further provides, according to independent claims 2 and 3 of that patent, a fatty acid ester of glycerol or a fatty acid ester of ethoxylated glycerol and / or a fatty acid ester of propoxylated glycerol. Discloses a ternary mixture of antimicrobially active topical pharmaceutical compositions, ie a mixture of fatty acids and pharmaceutically acceptable carriers, the fatty acids having a C _6-18 chain length. And a second fatty acid having a chain length of C _6-18 .

The wording of these generic fatty acids in fact generally includes dodecanoic acid and other fatty acids according to the invention. However, the antimicrobial activity described in this specification is essentially the basis of all the compositions described therein, the fatty acid ester of glycerol,
It only comes from the action of the fatty acid esters of ethoxylated glycerol and the fatty acids of propoxylated glycerol.

This specification is directed in a different direction than that provided by the present invention. Indeed, surprisingly, the addition of fatty acid esters of glycerol, ethoxylated glycerol, and / or fatty acid esters of propoxylated glycerol significantly reduces the antimicrobial effect of the mixture according to the invention of lauric acid and other fatty acids. And found that in some cases it even completely eliminated it at a given concentration.

Inert carriers and active constituents, which comprise C _4-14 chain-length fatty acids and their monoglycerides, and C _14-22 chain-length mono- or poly-saturated fatty acids and their monoglycerides. Also known from EP-A-0 465 423 are pharmaceutical compositions for combating microorganisms which essentially comprise an active amount of one or more compounds of choice). This specification also does not include any adaptations in the direction of the present invention.

Finally, it is also known to utilize the salts of the acids according to the invention in combination. However, they show no activity according to the invention. The mixtures according to the invention show their advantageous action against superinfection of the skin only at a pH in the range of 8 and below.

[0018]

Preferred compounds according to the present invention are caproic acid (hexanoic acid), caprylic acid (octanoic acid), pelargonic acid (nonanoic acid), capric acid (decanoic acid), myristic acid (tetradecanoic acid). C _6-20 fatty acid selected from the group consisting of, palmitic acid (hexadecanoic acid), and stearic acid (octadecanoic acid).

It is advantageous to choose the weight ratios given below, irrespective of whether a mixture of lauric acid and one or more other fatty acids is present, the ratio being: lauric acid: caproic acid = 50: 0 to 50: 5, and / or lauric acid: caprylic acid = 50: 1 to 50:20, and / or lauric acid: pelargonic acid = 50: 1 to 50:20, and / or lauric acid: capric acid = 50: 1 to 50:20, and / or lauric acid: myristic acid = 50: 5 to 50:30, and / or lauric acid: stearic acid = 50: 1 to 50:50.

The following weight ratios: lauric acid: caproic acid = 50: 0 to 50: 1, and / or lauric acid: caprylic acid = 50: 2 to 50:15, and / or lauric acid: pelargonic acid = 50. : 2 to 50:15, and / or lauric acid: capric acid = 50: 2 to 50:15, and / or lauric acid: myristic acid = 50:10 to 50:20, and / or lauric acid: stearic acid = It is particularly advantageous to choose 50: 2 to 50:20.

If lauric acid is present as a mixture with some other fatty acids, lauric acid, capric acid,
It is further preferred to use a mixture of and caprylic acid, which is in particular in the case of a weight ratio selected from the range lauric acid: caprylic acid: capric acid = 50: 1: 1 to 50:20:20. is there.

Therefore, this weight ratio is preferably selected from the range of lauric acid: caprylic acid: capric acid = 50: 1: 1 to 50: 5: 5.

A preferred embodiment of the present invention is the hydrogenation (hardening) of fatty acids from naturally occurring coconut fatty acid mixtures.
Selecting the ratio of lauric acid to other fatty acid (s) according to the invention, which corresponds to the ratio in the cut.

The composition of naturally occurring coconut fatty acids is approximately lauric acid: 44-51% by weight myristic acid: 13-18% by weight palmitic acid: 8-10% by weight caprylic acid: 6-9% by weight capric acid: 6 -10 wt% Oleic acid: 5-8 wt% Stearic acid: 1-3 wt% Linoleic acid: 0-2 wt% Caproic acid: 0-1 wt%.

The composition of the hardened (hydrogenated) coconut fatty acid is approximately lauric acid: 44-51% by weight myristic acid: 13-18% by weight palmitic acid: 8-10% by weight caprylic acid: 6-9% by weight capric acid: 6 to 10% by weight Stearic acid: 6 to 13% by weight Caproic acid: 0 to 1% by weight.

Lauric acid (CAS No. 143-07
-7) is, for example, Aarhus Oliefabrik
A / S Company, Aceto Chemical Comp
any Inc. Company, Dansk Soja-kage
Fabrik A / S, Proctor & Gam
ble Ltd. It is available from a variety of sources, including companies and other companies.

Hydrogenated coconut fatty acids are known as Ashlan.
d Hy from the Chemical Company
The name Edenor as drofol ™ acid (Acid) 631 and from Henkel KGaA.
(Trademark) HK 8-18.

Preference is given to the mixtures according to the invention of the following composition: lauric acid: 1-99% by weight myristic acid: 0-18% by weight palmitic acid: 0-10% by weight caprylic acid: 0-9% by weight capric acid. 0 to 10% by weight Stearic acid: 1 to 99% by weight Caproic acid: 0-1% by weight, the composition being in each case based on the total weight of the mixture.

Particularly advantageous compositions are those in which the composition according to the invention has the following composition: lauric acid: 10-90% by weight myristic acid: 13-18% by weight palmitic acid: 8-10% by weight caprylic acid: 6-9% by weight % Capric acid: 6-10% by weight stearic acid: 10-90% by weight caproic acid: 0-1% by weight, the composition of which in each case is based on the total weight of the mixture. There is.

Preferred compositions are those in which the composition of the mixture according to the invention comprises the following: lauric acid: 44-51% by weight myristic acid: 13-18% by weight palmitic acid: 8-10% by weight caprylic acid: 6-9% by weight. Capric acid: 6-10% by weight Stearic acid: 6-13% by weight Caproic acid: 0-1% by weight, obtained in particular when the composition is in each case based on the total weight of the mixture. There is.

In accordance with the present specification, Edenor ™
HK 8-18 is identified by the following approximate content of fatty acids according to the invention, which content is: lauric acid: 48% by weight myristic acid: 18% by weight palmitic acid: 8% by weight caprylic acid: 7% by weight. % Capric acid: 7% by weight stearic acid: 10% by weight caproic acid: 1% by weight, each case of its composition being based on the total weight of the mixture.

The use of this commercial product is advantageous.

In the dermatological preparation according to the invention, the content of the fatty acid mixture according to the invention is preferably 0.1-.
10.0% by weight, preferably 0.5-7.5% by weight, particularly preferably 1.5-5.0% by weight, the content of which in each case is the total weight of the mixture. Is based on.

The dermatological preparation according to the invention is in the form of an aerosol (that is a preparation which can be sprayed from an aerosol container, a squeeze bottle or by means of a pumping device) or a liquid which can be applied by means of a roll-on device. Not only can it be in the form of a composition, but it can also be in the form of a W / O or O / W emulsion, examples of which are creams or lotions, which are applied from common bottles and containers. can do. These formulations can also advantageously take the form of tinctures, shampoos, washes, showers or bath preparations, or powders or powder sprays.

Commercially available cosmetic carriers for dermatological preparations according to the invention, in addition to water, ethanol and isopropanol, glycerol and propylene glycol, decyl oleate, cetyl alcohol, cetylstearyl alcohol, and 2-octyl. It is possible to utilize skin-protecting lipids or lipid-like substances such as dodecanol, and viscous substances and thickeners such as hydroxyethyl- or hydroxypropylcellulose, polyacrylic acid or polyvinylpyrrolidone. There are, and in addition to these, small amounts of cyclic silicone oils (polydimethylsiloxanes) and low viscosity polymethylphenylsiloxanes.

Suitable propellants for the dermatological preparations according to the invention which can be nebulized from an aerosol container can be used by themselves or as a mixture with one another, for example hydrocarbons (propane, butane,
Alternatively, it is a commonly known volatile liquefied propellant such as isobutane). Compressed air can also be used to advantage.

Of course, the person skilled in the art is non-toxic in its own right and would theoretically be suitable for the present invention,
Nevertheless, we know that there are propellant gases, especially chlorofluorohydrocarbons (CFCs), which should be omitted due to unacceptable effects in the environment or other incidental situations.

Emulsifiers which have proved suitable for the preparation of dermatological preparations according to the invention and which are intended to be advantageously rolled on to the desired area of the skin as a liquid preparation by means of a roll-on device are used in an amount of 12 per molecule. Or 2
Polyoxyethylene fatty alcohol ethers, such as cetostearyl alcohol polyethylene glycol ether to which 0 ethylene oxide units have been added, cetostearyl alcohol, and sorbitan esters, and sorbitan ester-ethylene oxide compounds (eg,
Non-ionic types such as sorbitan monostearate and polyoxyethylene sorbitan monostearate), and long chain, higher molecular weight waxy polyglycol esters.

In addition to the components mentioned, perfumes, dyes,
Antioxidants (0.01 to 10.0% based on total composition), suspending agents, buffer mixtures and other commercially available cosmetic-based substances are added to the dermatological formulations according to the invention. It is preferred that this pH be brought to 4.0-7.5, especially 5.0-6.5, for example with conventional buffer mixtures.

Antioxidants include amino acids (eg, glycine, histidine, tyrosine, and tryptophan) and their derivatives, imidazoles (eg, urocanic acid) and their derivatives, D, L-carnosine, D.
-Peptides such as carnosine, L-carnosine and their derivatives (eg anserine), carcinoids, carotenes (eg α-carotene, β-carotene,
And lycopene) and their derivatives, lipoic acid and its derivatives (eg, dihydrolipoic acid), gold thioglucose, propylthiouracil, and other thiols (eg, thioredoxin, glutathione, cysteine, cystine, cystamine, and their glycosyl, N
-Acetyl, methyl, ethyl, propyl, amyl, butyl, and lauryl, palmitoyl, oleyl, γ-linoleyl, cholesteryl, and glyceryl esters) and their salts, dilaurine thiodipropionate, distearate thiodipropionate, thiodi Propionic acid, and their derivatives (esters, ethers, peptides, lipids, nucleotides, nucleosides, and salts), and very low tolerated doses (eg pmol
~ Μmol / kg) of a sulfoximine compound (eg, buthionine-sulfoximine, homocysteine-)
Sulfoxyimines, buthionine-sulfones, and penta-, hexa-, and heptathionine-sulfoxyimines), and (metal) chelating agents therefor (eg,
α-hydroxy-fatty acid, palmitic acid, phytic acid,
Or lactoferrin), α-hydroxy acid (eg citric acid, lactic acid, malic acid), humic acid, bile acid,
Bile extract, bilirubin, bilberdine, EDTA, E
GTA and their derivatives, unsaturated fatty acids and their derivatives (eg, γ-linolenic acid, linoleic acid,
And oleic acid), folic acid and its derivatives, ubiquinone and ubiquinol and their derivatives, vitamin C and derivatives (eg ascorbyl palmitate, ascorbyl phosphate Mg and ascorbate acetate), tocopherols and derivatives (eg Vitamin E acetate), vitamin A and derivatives (eg, vitamin A palmitate), and benzoin resin coniferyl benzoate, flavone, or flavonoid rutin acid, and their derivatives, ferulic acid and its derivatives, butylated hydroxy. Toluene, butylhydroxyanisole, nordihydroguaiac resin acid (nordihy
droguaiac resin), nordihydroguaiaretic acid, trihydroxybutyrophenone, uric acid and its derivatives, mannose and its derivatives, zinc and its derivatives (eg ZnO and Zn)
SO ₄ ), selenium and its derivatives (eg selenium-
Methionine), stilbene and its derivatives (eg,
Stilbene oxide and trans-stilbene), and derivatives of these active compounds described as suitable according to the invention (salts, esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids), in particular Advantageously selected.

For the present invention, it is essential that the pH of the preparation according to the invention which is active against superinfection of the skin is below 8. P slightly above 7 but below 7.5
H values are generally acceptable in the present invention. For a given fatty acid mixture, it is easy to determine the exact pH upper limit to be adhered to by simple trial and error in individual cases without dexterity.

The lower pH limit is determined solely by dermatological considerations. This is because common dermatological agents should not have pH values below about 3.5-4, and this range can be considered as the lower limit. Nevertheless, the compositions according to the invention are in principle active even at lower pH values.

The pH of the formulation according to the invention is below 8.
Preferably 4.0-7.5, particularly preferably 5.0-
It is conveniently adjusted in acid to a very weakly alkyl range of 6.5.

The amounts of auxiliaries, additives and carriers to be utilized in each case can easily be determined by the person skilled in the art by simple trial and error as a function of the specific product properties.

If appropriate, these substances and the perfume oils which are stable, are not irritating to the skin and have pre-existing antibacterial or bacteriostatic properties and are suitable for perfuming themselves.

The dermatological preparations are prepared in the usual manner, apart from the special preparations mentioned separately in the individual cases in the examples, which are usually accompanied by moderate heating, with stirring. By simple mixing. This preparation is never difficult. For emulsions, the oil and water phases are
For example, if appropriate, they are prepared separately with heating and then emulsified.

In other respects, the usual rules for formulating pharmaceutical formulations familiar to the person skilled in the art should be adhered to.

If the combination according to the invention is to be incorporated into a powder propellant, the suspension base for this is a silica gel (eg Aerosil ™).
, Diatomaceous earth, talc, modified starch, titanium dioxide, silk powder, nylon powder, polyethylene powder, and related substances.

[0049]

EXAMPLES The following are examples of advantageous embodiments of the present invention.

Example 1 Aerosol Spray I (a) Liquid phase wt% Octyldodecanol 0.50 Coconut fatty acid fraction 0.50 (Caproic acid 1% Caprylic acid 7% Capric acid 6% Lauric acid 48% Myristic acid 19% Stearic acid 10% included) Fragrance Sufficient Ethyl alcohol Amount up to 100.00 (b) Aerosol of liquid phase obtained in (a) with propane / butane 2.7 mixture in a ratio of 39:61 Transfer to a container.

Example 2 Aerosol Spray II (a) Liquid Phase Wt% Octyldodecanol 0.50 Coconut Fatty Acid Fraction (see Example 1) 0.20 Fragrance Sufficient Isopropyl Alcohol up to 100.00 (B) The liquid phase obtained in (a) is transferred to an aerosol container with a propane / butane 2.7 mixture in the ratio 39:61.

Example 3 Pump Spray I (a) Wt% Ethyl Alcohol 60.00 Glycerol 1.00 PEG 40-Hydrogenated Castor Oil 2.00 Coconut Fatty Acid Fraction (See Example 1) 0.50 Perfume Sufficient amount (b) Amount of water up to 100.00 Treat the components described in (a) to make a uniform solution,
And after that the aqueous phase (b) is slowly poured into it. The finished pump propellant can then be transferred to a pump atomizer.

Example 4 Roll-on gel I (a) wt% 1,3-butylene glycol 2.00 Hydroxyethylene cellulose 0.50 (eg Tylose 4000, Hoechst) (b) Water 100.00 Up to (c) Ethyl alcohol 60.00 PEG 40-hydrogenated castor oil 2.00 Fatty acid fraction of coconut (see Example 1) 0.30 Fragrance Sufficiently dispersed components described in (a). Water is added, the mixture is left to swell at room temperature, and after about 15 minutes a solution of the constituents described under (c) is added. The mixture formed can be homogenized and transferred to a container.

Example 5 Wax Stick Agent I Wt% Hydrogenated Castor Oil 5.00 Beeswax 6.00 Ceresin (hard ozokerite) 30.00 C _12-15 -Alkyl Benzoate 17.00 Fatty Acid Fraction of Coconut (Example 1 0.40 perfume sufficient octyldodecanol up to 100.00 The components are dissolved at about 75 ° C. and mixed thoroughly and the mixture cast into a suitable mold.

Example 6 Roll-on Emulsion I (a) wt% triceteareth phosphate 0.30 octyldodecanol 2.00 C _12-15 -alkyl benzoate 2.00 fatty acid fraction of coconut (Example 1 0.50 C _10-30 -alkyl acrylate 0.15 (b) Water 100.00 amount NaOH 0.05 (c) Ethyl alcohol 10.00 Perfume Sufficient amount (a) and ( The components described in b) are each heated to 75 ° C. with stirring. After that, the component (a) is added to (b). The mixture is cooled to 35 ° C. A solution is prepared from component (c), this is heated to 35 ° C. and added to the mixture of (a) and (b) with stirring.

Example 7 Aerosol Spray IV (a) Liquid Phase Wt% Octyldodecanol 0.50 Fatty Acid Mixture (See Example 7) 0.20 Fragrance Sufficient Isopropyl Alcohol up to 100.00 ( b) The liquid phase obtained in (a) is transferred to an aerosol container with a propane / butane 2.7 mixture in a ratio of 39:61.

Example 8 Pump Spray II (a) Wt% Ethyl Alcohol 60.00 Glycerol 1.00 PEG 40-Hydrogenated Castor Oil 2.00 Fatty Acid Mixture (See Example 7) 0.20 Perfume Sufficient ( b) Water up to 100.00 The components mentioned in (a) are treated to give a homogeneous solution, after which the aqueous phase (b) is slowly poured. The finished pump propellant can then be transferred to a pump atomizer.

Example 9 Roll-on gel II (a) wt% 1,3-butylene glycol 2.00 Hydroxyethylcellulose 0.50 (eg Tylose 4000, Hoechst) (b) Water up to 100.00 (C) Ethyl alcohol 60.00 PEG 40-hydrogenated castor oil 2.00 Fatty acid fraction (see Example 7) 0.30 Fragrance Sufficient amount of the components described in (a) are dispersed in water. (B) is added, the mixture is allowed to swell at room temperature, and after about 15 minutes a solution of the components described in (c) is added. The mixture formed can be homogenized and transferred to a container.

Example 10 Wax-sticking agent II wt% hydrogenated castor oil 5.00 Beeswax 6.00 Ceresin (hard ozokerite) 30.00 C _12-15 -Alkyl benzoate 17.00 Fatty acid mixture (see Example 7). So) 0.40 Perfume Sufficient Octyldodecanol up to 100.00 The components are dissolved at about 75 ° C. and mixed thoroughly and the mixture cast into a suitable mold.

Example 11 Roll-on Emulsion II (a) wt% triceteareth phosphate 0.30 octyldodecanol 2.00 C _12-15 -alkyl benzoate 2.00 fatty acid mixture (see Example 7). ) 0.50 C _10-30 -alkyl acrylate 0.15 (b) Water 100.00 amount NaOH 0.05 (c) Ethyl alcohol 10.00 Perfume In sufficient amount (a) and (b) The components described are each heated to 75 ° C. with stirring. After that, the component (a) is added to (b). The mixture is cooled to 35 ° C. A solution is prepared from component (c), this is heated to 35 ° C. and added to the mixture of (a) and (b) with stirring.

Example 12 Pump Spray III (a) Wt% Ethyl Alcohol 60.00 Glycerol 1.00 PEG 40-Hydrogenated Castor Oil 2.00 Fatty Acid Mixture (See Example 7) 0.50 Perfume Sufficient ( b) Water up to 100.00 The components mentioned in (a) are treated to give a homogeneous solution, after which the aqueous phase (b) is slowly poured. The finished pump propellant can then be transferred to a pump atomizer.

Example 13 Roll-on gel III (a) wt% 1,3-butylene glycol 2.00 Hydroxyethyl cellulose 0.50 (eg Tylose 4000, Hoechst) (b) Water until 100.00 (C) Ethyl alcohol 60.00 PEG 40-hydrogenated castor oil 2.00 Fatty acid fraction (see Example 7) 0.30 Fragrance Sufficient amount of the components described in (a) are dispersed in water. (B) is added, the mixture is allowed to swell at room temperature, and after about 15 minutes a solution of the components described in (c) is added. The mixture formed can be homogenized and transferred to a container.

Example 14 Wax Stick Agent III Wt% Hydrogenated Castor Oil 5.00 Beeswax 6.00 Ceresin (hard ozokerite) 30.00 C _12-15 -Alkyl Benzoate 17.00 Fatty Acid Mixture (see Example 7) So) 0.40 Perfume Sufficient Octyldodecanol up to 100.00 The components are dissolved at about 75 ° C. and mixed thoroughly and the mixture cast into a suitable mold.

Example 15 Roll-on Emulsion III (a) wt% triceteareth phosphate 0.30 octyldodecanol 2.00 C _12-15 -alkyl benzoate 2.00 fatty acid mixture (see Example 7). ) 0.50 C _10-30 -alkyl acrylate 0.15 (b) Water 100.00 amount NaOH 0.05 (c) Ethyl alcohol 10.00 Perfume In sufficient amount (a) and (b) The components described are each heated to 75 ° C. with stirring. After that, the component (a) is added to (b). The mixture is cooled to 35 ° C. A solution is prepared from component (c), this is heated to 35 ° C. and added to the mixture of (a) and (b) with stirring.

The main features or aspects of the present invention are as follows.

1. (A) dodecanoic acid (lauric acid),
(B) with at least one other fatty acid selected from the group consisting of unbranched saturated fatty acids having a chain length of C _6-20 ,
(C) Activity of a mixture of the active ingredients of (d) within a pH range of 8 or less excluding the fatty acid ester of glycerol, the fatty acid ester of ethoxylated glycerol, and the fatty acid ester of propoxylated glycerol against superinfection of skin Use as an ingredient.

2. Other saturated unbranched fatty acids are caproic acid (hexanoic acid), caprylic acid (octanoic acid), pelargonic acid (nonanoic acid), capric acid (decanoic acid), myristic acid (tetradecanoic acid), palmitic acid (hexadecanoic acid) And the use of stearic acid (octadecanoic acid).

3. The following weight ratios with respect to one another: lauric acid: caproic acid = 50: 0 to 50: 5, and / or lauric acid: caprylic acid = 50: 1 to 50:20, and / or lauric acid: pelargonic acid = 50: 1 to 50:20, and / or lauric acid: capric acid = 50: 1 to 50:20, and / or lauric acid: myristic acid = 50: 5 to 50:30, and / or lauric acid: stearic acid = 50 : 1-50: 50, preferably lauric acid: caproic acid = 50: 0-50: 1, and / or lauric acid: caprylic acid = 50: 2-50: 15, and / or lauric acid: pelargonic acid = 50: 2 to 50:15, and / or lauric acid: capric acid = 50: 2 to 50:15, and / or Gaulin acid: myristic acid = 50: 10-50: 20, and / or lauric acid: stearic acid = 50: 2 to 50: 20 fatty acids characterized by the presence, use according to the 1.

4. The following weight ratios with respect to each other: lauric acid: caprylic acid: capric acid = 50: 1: 1 to 50:20:20, preferably lauric acid: caprylic acid: capric acid = 50: 1: 1 to 50: 5. : 5. The use according to 1 above, wherein the fatty acid is present.

5. The mixture has the following composition: Lauric acid: 1-99% by weight Myristic acid: 0-18% by weight Palmitic acid: 0-10% by weight Caprylic acid: 0-9% by weight Capric acid: 0-10% by weight Stearic acid : 1 to 99% by weight caproic acid: 0 to 1% by weight, preferably lauric acid: 10 to 90% by weight myristic acid: 13 to 18% by weight palmitic acid: 8 to 10% by weight caprylic acid: 6 to 9% by weight Capric acid: 6 to 10% by weight Stearic acid: 10 to 90% by weight Caproic acid: 0 to 1% by weight, particularly preferably lauric acid: 44 to 51% by weight Myristic acid: 13 to 18% by weight Palmitic acid: 8 to 8% 10% by weight caprylic acid: 6 to 9% by weight capric acid: 6 to 10% by weight stearic acid: 6 to 13% by weight caproic acid: 0 It characterized by having a weight percent, the use of described in 1.

6. Use according to claim 1, characterized in that the proportion of fatty acids in relation to each other in the mixture corresponds to that which occurs in the hydrogenated (cured) fraction of fatty acids from naturally occurring coconut fatty acid mixtures.

7. The mixture is (a) lauric acid and other saturated unbranched fatty acids whose composition corresponds to the hydrogenated (cured) fraction of fatty acids from naturally occurring coconut fatty acid mixtures, or (b) such The use according to the above 1, characterized in that the distillate itself is included.

8. (A) dodecanoic acid (lauric acid),
(B) with at least one other fatty acid selected from the group consisting of unbranched saturated fatty acids having a chain length of C _6-20 ,
(C) A cosmetic product against skin superinfection of the active content of a mixture of (d) a pH range of 8 or less, wherein fatty acid ester of glycerol, fatty acid ester of ethoxylated glycerol, and fatty acid ester of propoxylated glycerol are excluded. Or for the preparation of dermatological preparations.

 ─────────────────────────────────────────────────── ─── Continuation of front page (72) Inventor Manfred Cleer Deutsche Day-21521 Aumiyure E-Sichupecht-Alley 11 (72) Inventor Manfred Lecle Germany 22880 Bedel Erbschtütraße 5

Claims (2)

[Claims] 1. (a) dodecanoic acid (lauric acid) and (b) at least one other fatty acid selected from the group consisting of unbranched saturated fatty acids having a chain length of C _6-20 , c) a fatty acid ester of glycerol, a fatty acid ester of ethoxylated glycerol, and a fatty acid ester of propoxylated glycerol are excluded, (d) an active ingredient against skin superinfection of the active content of the mixture of within the pH range of 8 Use as. 2. (a) dodecanoic acid (lauric acid) and (b) at least one other fatty acid selected from the group consisting of unbranched saturated fatty acids having a chain length of C _6-20 , c) a fatty acid ester of glycerol, a fatty acid ester of ethoxylated glycerol and a fatty acid ester of propoxylated glycerol are excluded, (d) a cosmetic composition against skin superinfection of an active content of a mixture of (d) within a pH range of 8 or less Or use for the preparation of dermatological preparations.